Feasibility of IA thrombolysis for acute ischemic stroke among anticoagulated patients.
OBJECTIVE
Limited information exists regarding thrombolysis among anticoagulated acute stroke patients. We present data from three consecutive patients, on active warfarin therapy, treated with intra-arterial reteplase.


METHODS
All patients were screened for the presence of intracranial hemorrhage. Warfarin was reversed with fresh frozen plasma in all patients and cerebral angiography and intra-arterial administration of reteplase was performed. Computed tomographic scans were performed to detect any subsequent intracranial hemorrhage. Ages ranged from 58 to 79 years with initial National Institutes of Health Stroke Scale scores ranging from 12 to 17. Baseline international normalized ratios (INRs) were 1.99-2.25. None of the patients suffered from intracranial hemorrhage following thrombolysis, and two of the patients experienced early neurological improvement.


CONCLUSIONS
Low dose, intra-arterial reteplase following acute reversal of elevated INR is feasible and may offer a potential treatment for patients suffering with acute ischemic stroke while receiving active warfarin treatment.
Janjua
Nazli
N
Department of Neurology, Long Island College Hospital, 339 Hicks St., Brooklyn, NY 11201, USA. NJanjua@chpnet.com
Alkawi
Ammar
A
Georgiadis
Alexandros
A
Suri
M Fareed K
MF
Ibrahim
M Salim
MS
Kirmani
Jawad F
JF
Qureshi
Adnan I
AI
D000208:Acute Disease; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy; D002533:Cerebral Angiography; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007269:Injections, Intra-Arterial; D020300:Intracranial Hemorrhages / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D020521:Stroke / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014859:Warfarin / Q000008:administration & dosage*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014859:Warfarin; C087896:reteplase; D010959:Tissue Plasminogen Activator